Quick Answer
FILANA THERAPEUTICS, INC. reported Total Revenue of $41.12 million for fiscal year 2013.
FILANA THERAPEUTICS, INC. — Key Financials by Year
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 |
|---|---|---|---|---|---|---|
| Total Revenue | — | — | — | — | — | — |
| Net Income | -$90.97M -273.7% |
-$24.34M +75.0% |
-$97.22M -27.5% |
-$76.25M -135.4% |
-$32.38M -411.3% |
-$6.33M -36.8% |
| Diluted EPS | -$1.88 -28.8% |
-$1.46 +37.1% |
-$2.32 -22.1% |
-$1.90 | — | — |
| Total Assets | $118.36M -24.9% |
$157.53M +3.9% |
$151.66M -35.4% |
$234.83M -12.0% |
$266.78M +182.9% |
$94.30M +301.5% |
| Cash and Equivalents | $95.50M -25.7% |
$128.57M +6.1% |
$121.14M -39.7% |
$201.01M -13.9% |
$233.44M +149.6% |
$93.51M +305.1% |
| Stockholders Equity | $74.40M -48.9% |
$145.70M +6.0% |
$137.47M -39.6% |
$227.54M -10.4% |
$253.91M +175.4% |
$92.20M +317.2% |
| R&D Expense | $26.59M -61.8% |
$69.64M -22.1% |
$89.42M +31.4% |
$68.03M +174.2% |
$24.81M | — |
| Operating Income | -$95.39M +32.6% |
-$141.45M -33.5% |
-$105.96M -32.4% |
-$80.02M -143.5% |
-$32.87M -409.9% |
-$6.45M -30.0% |
| Shares Outstanding | 48.31M +0.2% |
48.20M +14.1% |
42.24M +1.2% |
41.74M +4.3% |
40.02M +13.6% |
35.24M +61.3% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | September 30, 2013 | $1.96M | -28.1% | -0.1% |
| Net Income | September 30, 2025 | -$10.81M | +61.3% | +75.6% |
| Diluted EPS | September 30, 2025 | -$0.22 | +62.1% | +76.1% |
| Total Assets | September 30, 2025 | $129.73M | -42.0% | -4.2% |
| Cash and Equivalents | September 30, 2025 | $106.08M | -28.8% | -5.6% |
| Stockholders Equity | September 30, 2025 | $81.57M | -51.1% | -7.3% |
| R&D Expense | September 30, 2025 | $3.96M | -77.6% | -22.7% |
| Operating Income | September 30, 2025 | -$11.86M | +61.3% | +73.9% |
| Shares Outstanding | September 30, 2025 | 48.31M | +0.7% | +0.0% |
- FILANA THERAPEUTICS, INC. reported Total Revenue of $41.12 million for fiscal year 2013.
- FILANA THERAPEUTICS, INC. showed an increase of +277.6% in Total Revenue compared to the prior fiscal year.
- FILANA THERAPEUTICS, INC. reported Net Income of -$90.97 million for fiscal year 2025.
- FILANA THERAPEUTICS, INC. showed a decrease of -273.7% in Net Income compared to the prior fiscal year.
- FILANA THERAPEUTICS, INC. reported Diluted EPS of $1.88 per share (loss) for fiscal year 2025.
- FILANA THERAPEUTICS, INC. showed a decrease of -28.8% in Diluted EPS compared to the prior fiscal year.
- FILANA THERAPEUTICS, INC. reported Total Assets of $118.36 million for fiscal year 2025.
- FILANA THERAPEUTICS, INC. showed a decrease of -24.9% in Total Assets compared to the prior fiscal year.
- FILANA THERAPEUTICS, INC. reported Cash and Equivalents of $95.50 million for fiscal year 2025.
- FILANA THERAPEUTICS, INC. showed a decrease of -25.7% in Cash and Equivalents compared to the prior fiscal year.
- FILANA THERAPEUTICS, INC. reported Stockholders Equity of $74.40 million for fiscal year 2025.
- FILANA THERAPEUTICS, INC. showed a decrease of -48.9% in Stockholders Equity compared to the prior fiscal year.
- FILANA THERAPEUTICS, INC. reported R&D Expense of $26.59 million for fiscal year 2025.
- FILANA THERAPEUTICS, INC. showed a decrease of -61.8% in R&D Expense compared to the prior fiscal year.
- FILANA THERAPEUTICS, INC. reported Operating Income of -$95.39 million for fiscal year 2025.
- FILANA THERAPEUTICS, INC. showed an increase of +32.6% in Operating Income compared to the prior fiscal year.
- FILANA THERAPEUTICS, INC. reported Shares Outstanding of 48.31 million shares for fiscal year 2025.
- FILANA THERAPEUTICS, INC. showed an increase of +0.2% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: